Artiva Biotherapeutics, Inc., a clinical-stage company focused on delivering off-the-shelf NK cell-based therapies, appointed Neha Krishnamohan as CFO and EVP, Corporate Development, and promoted Jennifer Bush to COO. Krishnamohan’s financial and strategic expertise, along with Bush’s contributions since 2020, are anticipated to bolster Artiva’s growth and strategic goals.
“I am very pleased to welcome Neha to our team,” said Fred Aslan, M.D., CEO of Artiva. “Neha’s perspectives as a finance industry executive and long-standing Wall Street experience as an investment banker will be valuable as we pursue our mission to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers.”
Before joining Artiva, Neha Krishnamohan served as the CFO and EVP, Corporate Development at Kinnate Biopharma Inc., where she led financial operations, business development, and investor relations. She was instrumental in exploring strategic alternatives, leading to a successful asset sale. Prior to Kinnate, she worked as a Vice President in the Healthcare Investment Banking Group at Goldman Sachs for over 12 years, executing over $100 billion in transactions in the biopharmaceutical sector. Neha holds a B.S.E in biomedical engineering and economics from Duke University and serves on the board of directors of Arcutis Biotherapeutics, Inc.
“I am honored to be joining Artiva,” said Ms. Krishnamohan. “Artiva has the potential to transform the treatment of patients with autoimmune diseases through its differentiated ‘manufacturing first’ approach to NK cell therapies bringing expanded accessibility and availability relative to autologous cell therapy.”
Jennifer Bush, promoted to COO, is a seasoned leader in corporate strategy, legal, regulatory, and operations. She joined Artiva in 2020 as General Counsel and became Chief Legal & People Officer in 2021. Jennifer’s extensive experience includes roles at Organovo, Inc., and Broadcom. She received her B.A. in history and Latin American studies from Princeton University and her J.D. from Yale Law School.
“At Artiva, people are our most important asset,” said Dr. Aslan. “Jennifer has been instrumental negotiating our key strategic transactions, financing the company through offerings that have raised over $200 million, and building and leading Artiva’s legal, people and culture, finance, information technology, and administrative functions.”
About Artiva Biotherapeutics:
Artiva is a clinical-stage company focused on delivering NK cell-based therapies to patients with autoimmune diseases and cancers. Their lead program, AlloNK®, aims to enhance the activity of monoclonal antibodies for B-cell depletion. Artiva’s pipeline includes CAR-NK candidates targeting solid and hematologic cancers. They are headquartered in San Diego.
